Ten new recommendations for more patient-centric innovation and properly assess benefits of value added medicines, according to the new study “Value added Medicines: time to adjust the HTA decision Frameworks”

The Health Technology Assessment (HTA) is a system for assessing innovation in the healthcare systems of European countries.

Though it has helped to achieve better pateient access to therapies, the HTA system can be improved, at least according to the new study “Value added Medicines: time to adjust the HTA decision Frameworks” launched in September by the Value Added Medicines group, a sector group of Medicines For Europe.

The study, conducted by Mondher Toumi, Professor of Public Health at Aix-Marseille University, highlights the need for adjustments in HTA decision frameworks to ensure that European patients can benefit from value added medicines, that “represent an opportunity for increasing the cost-effectiveness of treatments or services that may bring substantial value to individual patients and society. However, the current European HTA decision frameworks represent various challenges for the full value recognition ...